8月19日早间歌礼制药在港交所公告于2025年8月19日(交易时段前)本公司、补足卖方与配售代理订立配售及认购协议据此补

智通财经
Aug 19, 2025
8月19日早间歌礼制药在港交所公告于2025年8月19日(交易时段前)本公司、补足卖方与配售代理订立配售及认购协议据此补足卖方同意出售而配售代理同意作为补足卖方代理促使承配人(将为专业、机构、企业或其他投资者)购买补足卖方所持有52,400,000股股份;补足卖方有条件同意认购而本公司有条件同意按配售价发行28,820,000股新股份。配售价为每股股份16.45港元较8月18日(即最后交易日)于联交所所报的收市价每股股份18.26港元折让约9.9%。认购所得款项净额(经扣除佣金及估计开支后)预期合共约为467.69百万港元约90%建议用于其皮下注射多肽及口服多肽候选药物有关之肥胖症临床试验研发约10%建议用作营运资金及其他一般公司用途。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10